Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis

NCT00396422 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Small Plaque Psoriasis

Interventions

DRUG: RWJ-445380

Sponsor

Alza Corporation, DE, USA